400 related articles for article (PubMed ID: 30054667)
21. Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas.
Gousias K; von Ruecker A; Voulgari P; Simon M
J Neuroimmunol; 2013 Nov; 264(1-2):84-90. PubMed ID: 24071056
[TBL] [Abstract][Full Text] [Related]
22. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
23. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
[TBL] [Abstract][Full Text] [Related]
24. Antitumor CD8 T cell responses in glioma patients are effectively suppressed by T follicular regulatory cells.
Lu L; Sun J; Su H; Luo S; Chen J; Qiu S; Chi Y; Lin J; Xu X; Zheng D
Exp Cell Res; 2021 Oct; 407(2):112808. PubMed ID: 34508744
[TBL] [Abstract][Full Text] [Related]
25. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
26. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
27. Galectin-1 and immunotherapy for brain cancer.
Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
[TBL] [Abstract][Full Text] [Related]
28. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.
Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H
J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813
[TBL] [Abstract][Full Text] [Related]
29. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
[TBL] [Abstract][Full Text] [Related]
30. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
31. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
Saha A; Chatterjee SK
Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
[TBL] [Abstract][Full Text] [Related]
32. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
[TBL] [Abstract][Full Text] [Related]
33. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G
J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810
[TBL] [Abstract][Full Text] [Related]
34. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
35. The role of regulatory T cells in malignant glioma.
Sonabend AM; Rolle CE; Lesniak MS
Anticancer Res; 2008; 28(2B):1143-50. PubMed ID: 18505050
[TBL] [Abstract][Full Text] [Related]
36. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
37. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy for human glioma: innovative approaches and recent results.
Hussain SF; Heimberger AB
Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
[TBL] [Abstract][Full Text] [Related]
39. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
40. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma.
Chiba Y; Hashimoto N; Tsuboi A; Oka Y; Murao A; Kinoshita M; Kagawa N; Oji Y; Hosen N; Nishida S; Sugiyama H; Yoshimine T
Jpn J Clin Oncol; 2010 May; 40(5):395-403. PubMed ID: 20364021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
